Author’s Reply to Peronard and Mayntz: “SGLT2 Inhibitors, and How They Work Beyond the Glucosuric Effect”
No hay miniatura disponible
Fecha
2024
Autores
Aristizábal‑Colorado, David
Ocampo‑Posada, Martín
Rivera‑Martínez, Wilfredo Antonio
Corredor‑Rengifo, David
Rico‑Fontalvo, Jorge
Gómez‑Mesa, Juan Esteban
Duque‑Ossman, John Jairo
Abreu‑Lomba, Alin
Título de la revista
ISSN de la revista
Título del volumen
Editor
Springer Nature
Resumen
We would like to express our sincere gratitude to the
reviewers for their thoughtful and detailed comments on
our article. We hope that our responses adequately address
their concerns and that this exchange of ideas contributes to
a broader understanding of the topic. We believe that letters
to the editor serve as valuable platforms for scholarly discussion
and the dissemination of knowledge. We encourage
continued dialogue and debate on this important subject.
Descripción
Palabras clave
Citación
Aristizábal-Colorado, D., Ocampo-Posada, M., Rivera-Martínez, W.A. et al. Author’s Reply to Peronard and Mayntz: “SGLT2 Inhibitors, and How They Work Beyond the Glucosuric Effect”. Am J Cardiovasc Drugs (2024). https://doi.org/10.1007/s40256-024-00707-8
